Budget 2018-19

  Supplies of medical oxygen, essential in many cases to treat seriously ill patients, have been depleted as hospitals around India have been overwhelmed by Covid-19 cases An acute shortage of medical oxygen in India, amid a deadly wave of coronavirus infections, has triggered a surge in stocks seen linked to industrial gases. Supplies of medical oxygen, essential in many cases to treat seriously ill patients, have been depleted as hospitals around India have been overwhelmed by Covid-19 cases. The nation recorded 314,835 new infections on Thursday, the world’s biggest one-day jump, and taking its case-count to almost 16 million, the second-most globally. Workers load refilled oxygen tanks into a vehicle at a refill station in Navi Mumbai, India, on Thursday, April 22, 2021. India saw a record one-day jump with more than 300,000 new coronavirus infections, marking a grim milestone for the country as a deadlier second wave showing no signs of abating. Chart Oxygen manufacturer Linde...

  As of now, Covax has not disclosed the India distribution plan for the Pfizer-BioNTech vaccine According to the interim distribution forecast released by Covax, the World Health Organization (WHO)-Gavi initiative to ensure equitable distribution of vaccine across the globe, India will get around 97 million doses of the AstraZeneca vaccine made by Serum Institute of India (SII). As of now, Covax has not allotted the Pfizer-BioNTech vaccine for India. The document highlights that India is in line to receive around 97,164,000 doses of AstraZeneca vaccine licensed to SII in the first and second quarters of 2021. The Covax plan states how the 240 mn doses of the AstraZeneca-Oxford vaccine would be distributed across countries as well as the 1.2 million doses of the  Pfizer-BioNTech vaccine . “Covax currently anticipates 1.2 million doses of the Pfizer-BioNTech vaccine will be available to the COVAX Facility in Q1 2021, subject to the completion of additional agreements, and will ...

  Pfizer-BioNTech vaccine candidate, BNT162b2, was 90% effective in preventing infection during the phase 3 clinical trial, which enrolled 43,538 participants, with 30% in U.S. and 42% abroad As the weather cools, the number of infections of the COVID-19 pandemic are rising sharply. Hamstrung by pandemic fatigue, economic constraints and political discord, public health officials have struggled to control the surging pandemic. But now, a rush of interim analyses from pharmaceutical companies Moderna and Pfizer/BioNTech have spurred optimism that a novel type of vaccine made from messenger RNA, known as mRNA, can offer high levels of protection by preventing  COVID-19  among people who are vaccinated. Although unpublished, these preliminary reports have exceeded the expectations of many vaccine experts, including mine. Until early this year, I worked on developing vaccine candidates against Zika and dengue. Now I am coordinating an international effort to collect reports o...